ELOX
Eloxx Pharmaceuticals, Inc.
Price Chart
Latest Quote
$13.52
+0.88 (+6.96%)
Current Price
| Previous Close | $12.64 |
| Open | $13.90 |
| Day High | $15.86 |
| Day Low | $11.40 |
| Volume | 51,448 |
Stock Information
| Shares Outstanding | 3.44M |
| Total Debt | $11.82M |
| Cash Equivalents | $6.36M |
| Net Income | $-8.04M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $46.46M |
| EPS (TTM) | $-1.32 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $14.16M |
| Income | $-8.04M |
| Book/sh | $-16.45 |
| Cash/sh | $1.85 |
| Employees | 10 |
Financial Ratios
| Quick Ratio | 0.40 |
| Current Ratio | 0.53 |
Returns & Margins
Ownership
| Insider Ownership | 0.93% |
| Institutional Ownership | 0.83% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -19.04 |
| PEG | 1.85 |
| P/B | -0.82 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 532K |
| Short Float | 1.33% |
| Short Ratio | 1.22 |
| Volatility | -168027.67 |
Performance History
| YTD | +22.80% |
| 10 Years | +22.80% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $13.52 | 51,400 |
| 2026-06-11 | $12.64 | 33,800 |
| 2026-06-10 | $11.00 | 119,200 |
| 2026-06-09 | $11.01 | 284,500 |
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
đ° Latest News
No news articles available at the moment. Check back later for updates on ELOX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $6,359,000 | $0 | $0 |
| Operating Revenue | $0 | $6,359,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,049,000 | $1,144,000 | $1,151,000 | $1,949,000 |
| Total Expenses | $6,438,000 | $8,827,000 | $17,288,000 | $34,419,000 |
| Other Income Expense | $1,305,000 | $442,000 | $1,133,000 | $29,000 |
| Other Non Operating Income Expenses | $-27,000 | $53,000 | $-262,000 | $77,000 |
| Net Non Operating Interest Income Expense | $-862,000 | $-1,117,000 | $-899,000 | $-1,675,000 |
| Total Other Finance Cost | $-154,000 | - | - | - |
| Interest Expense Non Operating | $1,049,000 | $1,144,000 | $1,151,000 | $1,949,000 |
| Operating Expense | $6,438,000 | $8,827,000 | $17,288,000 | $34,419,000 |
| General And Administrative Expense | $3,382,000 | $5,250,000 | $8,690,000 | $10,692,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,995,000 | $-3,143,000 | $-17,054,000 | $-36,065,000 |
| Net Interest Income | $-862,000 | $-1,117,000 | $-899,000 | $-1,675,000 |
| Interest Income | $33,000 | $27,000 | $252,000 | $274,000 |
| Normalized Income | $-7,327,000 | $-3,532,000 | $-18,449,000 | $-36,017,000 |
| Net Income From Continuing And Discontinued Operation | $-5,995,000 | $-3,143,000 | $-17,054,000 | $-36,065,000 |
| Net Income Common Stockholders | $-5,995,000 | $-3,143,000 | $-17,054,000 | $-36,065,000 |
| Net Income | $-5,995,000 | $-3,143,000 | $-17,054,000 | $-36,065,000 |
| Net Income Including Noncontrolling Interests | $-5,995,000 | $-3,143,000 | $-17,054,000 | $-36,065,000 |
| Net Income Continuous Operations | $-5,995,000 | $-3,143,000 | $-17,054,000 | $-36,065,000 |
| Pretax Income | $-5,995,000 | $-3,143,000 | $-17,054,000 | $-36,065,000 |
| Special Income Charges | $1,237,000 | $13,000 | $-148,000 | $0 |
| Interest Income Non Operating | $33,000 | $27,000 | $252,000 | $274,000 |
| Operating Income | $-6,438,000 | $-2,468,000 | $-17,288,000 | $-34,419,000 |
| Per Share | ||||
| Diluted EPS | $-5.39 | $-9.24 | $-72.93 | $-183.15 |
| Basic EPS | $-5.39 | $-9.24 | $-72.93 | $-183.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,278,000 | $-2,224,000 | $-16,489,000 | $-33,373,000 |
| Total Unusual Items | $1,332,000 | $389,000 | $1,395,000 | $-48,000 |
| Total Unusual Items Excluding Goodwill | $1,332,000 | $389,000 | $1,395,000 | $-48,000 |
| Reconciled Depreciation | $0 | $164,000 | $809,000 | $695,000 |
| EBITDA (Bullshit earnings) | $-4,946,000 | $-1,835,000 | $-15,094,000 | $-33,421,000 |
| EBIT | $-4,946,000 | $-1,999,000 | $-15,903,000 | $-34,116,000 |
| Diluted Average Shares | $1,122,499 | $341,709 | $233,692 | $196,937 |
| Basic Average Shares | $1,122,499 | $341,709 | $233,692 | $196,937 |
| Diluted NI Availto Com Stockholders | $-5,995,000 | $-3,143,000 | $-17,054,000 | $-36,065,000 |
| Gain On Sale Of Ppe | $1,000 | $38,000 | $288,000 | - |
| Other Special Charges | $-1,236,000 | $25,000 | $436,000 | - |
| Gain On Sale Of Security | $95,000 | $376,000 | $1,543,000 | $-48,000 |
| Research And Development | $3,056,000 | $3,577,000 | $8,598,000 | $23,727,000 |
| Selling General And Administration | $3,382,000 | $5,250,000 | $8,690,000 | $10,692,000 |
| Other Gand A | $3,382,000 | $5,250,000 | $8,690,000 | $10,692,000 |
| Restructuring And Mergern Acquisition | - | - | - | - |
Fetched: 2026-06-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-11,907,000 | $-24,335,000 | $-22,599,000 | $-10,660,000 |
| Total Assets | $5,270,000 | $2,976,000 | $1,712,000 | $21,123,000 |
| Total Non Current Assets | $0 | $0 | $164,000 | $994,000 |
| Current Assets | $5,270,000 | $2,976,000 | $1,548,000 | $20,129,000 |
| Other Current Assets | $479,000 | $142,000 | $194,000 | $568,000 |
| Restricted Cash | $6,000 | $5,000 | $220,000 | $261,000 |
| Receivables | $0 | $2,718,000 | $0 | - |
| Accounts Receivable | $0 | $2,359,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $4,785,000 | $111,000 | $1,134,000 | $19,207,000 |
| Cash And Cash Equivalents | $4,785,000 | $111,000 | $1,134,000 | $19,207,000 |
| Other Receivables | - | $359,000 | - | - |
| Prepaid Assets | - | - | - | $93,000 |
| Debt | ||||
| Total Debt | $1,000,000 | $6,520,000 | $3,966,000 | $13,384,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $0 | $1,614,000 | $8,692,000 |
| Current Debt And Capital Lease Obligation | $1,000,000 | $6,520,000 | $2,352,000 | $4,692,000 |
| Current Debt | $1,000,000 | $6,516,000 | $2,219,000 | $3,980,000 |
| Other Current Borrowings | $1,000,000 | $6,516,000 | $2,219,000 | $3,980,000 |
| Net Debt | - | $6,405,000 | $2,697,000 | - |
| Long Term Debt | - | - | $1,612,000 | $8,557,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $17,177,000 | $27,311,000 | $24,311,000 | $31,783,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $1,614,000 | $8,692,000 |
| Current Liabilities | $17,177,000 | $27,311,000 | $22,697,000 | $23,091,000 |
| Current Deferred Liabilities | $11,816,000 | $13,347,000 | $12,966,000 | $12,535,000 |
| Payables And Accrued Expenses | $4,361,000 | $7,349,000 | $6,908,000 | $5,819,000 |
| Interest Payable | $35,000 | $557,000 | $48,000 | $146,000 |
| Payables | $2,713,000 | $5,346,000 | $5,699,000 | $3,020,000 |
| Accounts Payable | $2,713,000 | $5,346,000 | $5,699,000 | $3,020,000 |
| Other Current Liabilities | - | $95,000 | $471,000 | $45,000 |
| Equity | ||||
| Common Stock Equity | $-11,907,000 | $-24,335,000 | $-22,599,000 | $-10,660,000 |
| Total Equity Gross Minority Interest | $-11,907,000 | $-24,335,000 | $-22,599,000 | $-10,660,000 |
| Stockholders Equity | $-11,907,000 | $-24,335,000 | $-22,599,000 | $-10,660,000 |
| Retained Earnings | $-300,580,000 | $-294,585,000 | $-291,442,000 | $-274,388,000 |
| Other | ||||
| Ordinary Shares Number | $435,476 | - | $278,944 | $196,941 |
| Share Issued | $435,476 | - | $278,944 | $196,941 |
| Tangible Book Value | $-11,907,000 | $-24,335,000 | $-22,599,000 | $-10,660,000 |
| Invested Capital | $-10,907,000 | $-17,819,000 | $-18,768,000 | $1,877,000 |
| Working Capital | $-11,907,000 | $-24,335,000 | $-21,149,000 | $-2,962,000 |
| Capital Lease Obligations | $0 | $4,000 | $135,000 | $847,000 |
| Total Capitalization | $-11,907,000 | $-24,335,000 | $-20,987,000 | $-2,103,000 |
| Additional Paid In Capital | $288,625,000 | $270,215,000 | $268,812,000 | $263,706,000 |
| Capital Stock | $48,000 | $35,000 | $31,000 | $22,000 |
| Common Stock | $48,000 | $35,000 | $31,000 | $22,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $0 | $2,000 | $135,000 |
| Current Deferred Revenue | $11,816,000 | $13,347,000 | $12,966,000 | $12,535,000 |
| Current Capital Lease Obligation | $0 | $4,000 | $133,000 | $712,000 |
| Current Accrued Expenses | $1,648,000 | $2,003,000 | $1,209,000 | $2,799,000 |
| Net PPE | $0 | $0 | $164,000 | $994,000 |
| Accumulated Depreciation | $0 | $0 | $-278,000 | $-180,000 |
| Gross PPE | $0 | $0 | $442,000 | $1,174,000 |
| Leases | $0 | $0 | $57,000 | $57,000 |
| Machinery Furniture Equipment | $0 | $0 | $41,000 | $41,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Properties | - | - | $344,000 | $1,076,000 |
| Treasury Shares Number | - | - | - | $0 |
| Treasury Stock | - | - | - | $0 |
| Construction In Progress | - | - | - | $0 |
| Dueto Related Parties Current | - | - | - | - |
Fetched: 2026-06-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,327,000 | $-4,715,000 | $-14,341,000 | $-31,911,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,327,000 | $-4,715,000 | $-14,341,000 | $-31,845,000 |
| Cash Flow From Continuing Operating Activities | $-6,327,000 | $-4,715,000 | $-14,341,000 | $-31,845,000 |
| Operating Gains Losses | $-1,332,000 | $-389,000 | $-1,395,000 | $45,000 |
| Investing Activities | ||||
| Investing Cash Flow | $1,000 | $38,000 | $309,000 | $-66,000 |
| Cash Flow From Continuing Investing Activities | $1,000 | $38,000 | $309,000 | $-66,000 |
| Capital Expenditure | - | - | - | $-66,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $4,888,000 | $0 |
| Financing Cash Flow | $11,001,000 | $3,439,000 | $-4,082,000 | $8,812,000 |
| Cash Flow From Continuing Financing Activities | $11,001,000 | $3,439,000 | $-4,082,000 | $8,812,000 |
| Net Other Financing Charges | $-300,000 | $381,000 | $431,000 | $8,812,000 |
| Net Common Stock Issuance | $0 | $0 | $4,888,000 | $0 |
| Common Stock Issuance | $0 | $0 | $4,888,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-1,255,000 | $-610,000 | $-9,401,000 | $0 |
| Issuance Of Debt | $2,865,000 | $3,668,000 | $0 | $0 |
| Interest Paid Supplemental Data | $25,000 | $139,000 | $989,000 | $1,365,000 |
| End Cash Position | $4,791,000 | $116,000 | $1,354,000 | $19,468,000 |
| Beginning Cash Position | $116,000 | $1,354,000 | $19,468,000 | $42,567,000 |
| Changes In Cash | $4,675,000 | $-1,238,000 | $-18,114,000 | $-23,099,000 |
| Proceeds From Stock Option Exercised | $9,691,000 | $0 | $0 | $0 |
| Net Issuance Payments Of Debt | $1,610,000 | $3,058,000 | $-9,401,000 | $0 |
| Net Long Term Debt Issuance | $1,610,000 | $3,058,000 | $-9,401,000 | $0 |
| Long Term Debt Payments | $-1,255,000 | $-610,000 | $-9,401,000 | $0 |
| Long Term Debt Issuance | $2,865,000 | $3,668,000 | $0 | $0 |
| Net PPE Purchase And Sale | $1,000 | $38,000 | $309,000 | $-66,000 |
| Sale Of PPE | $1,000 | $38,000 | $309,000 | - |
| Change In Working Capital | $520,000 | $-2,356,000 | $844,000 | $-118,000 |
| Change In Other Working Capital | $359,000 | $-359,000 | - | - |
| Change In Other Current Liabilities | $-4,000 | $-131,000 | $-712,000 | $-614,000 |
| Change In Payables And Accrued Expense | $-1,857,000 | $441,000 | $1,089,000 | $244,000 |
| Change In Accrued Expense | $776,000 | $794,000 | $-1,590,000 | $-1,397,000 |
| Change In Payable | $-2,633,000 | $-353,000 | $2,679,000 | $1,641,000 |
| Change In Account Payable | $-2,633,000 | $-353,000 | $2,679,000 | $1,641,000 |
| Change In Prepaid Assets | $-337,000 | $52,000 | $467,000 | $252,000 |
| Change In Receivables | $2,359,000 | $-2,359,000 | $0 | - |
| Changes In Account Receivables | $2,359,000 | $-2,359,000 | $0 | - |
| Other Non Cash Items | $245,000 | $468,000 | $490,000 | $541,000 |
| Stock Based Compensation | $235,000 | $541,000 | $1,965,000 | $3,021,000 |
| Depreciation Amortization Depletion | $0 | $164,000 | $809,000 | $695,000 |
| Depreciation And Amortization | $0 | $164,000 | $809,000 | $695,000 |
| Depreciation | $0 | $164,000 | $809,000 | $695,000 |
| Gain Loss On Investment Securities | $-95,000 | $-376,000 | $-1,543,000 | $45,000 |
| Gain Loss On Sale Of PPE | $-1,000 | $-38,000 | $-288,000 | $0 |
| Net Income From Continuing Operations | $-5,995,000 | $-3,143,000 | $-17,054,000 | $-36,065,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $-66,000 |
| Asset Impairment Charge | - | - | - | $36,000 |
| Income Tax Paid Supplemental Data | - | - | - | - |
| Net Investment Purchase And Sale | - | - | - | - |
| Sale Of Investment | - | - | - | - |
| Purchase Of Investment | - | - | - | - |
| Amortization Of Securities | - | - | - | - |
Fetched: 2026-06-13